Additional data files has been uploaded to the RAW data section of the repository. 

Patient and sample characteristics

More detailed clinical information is available in a separate document

 ^anumber of days between the first and the last time point in the disease, measured by mass spectrometry (MS)

^beach sample represents serum of a distinct time point in the disease course, analyzed by serum protein electrophoresis (SPEP) and excised for MS measurement,

De novo sequence results for the selected multiple myeloma patients.

^a de novo sequences derived from targeted measurements is shown, with differences to DDA based data

^b The peptide was monitored with all methionine residues in the oxidized form

^c ALC = average local confidence score from PEAKS

^d The germline peptide lacks an N-terminal tryptic site.

Sequence, m/z, charge states and fragment types of selected patient-specific M-protein peptides used for M-protein monitoring with targeted mass spectrometry.

[Ox] = oxidation

[CAM] = carbamidomethylation

DNA and de novo sequencing results of the reference patient.

Differences between the patient specific M-protein and the most homologous germline sequence are bold. Differences between the de novo sequencing result and the DNA-derived sequence are in red. No light chain DNA data was available to validate sequences obtained from de novo sequencing for the light chain. Trypsin cleavage sites are indicated with | symbols.